Application Of Lutein Research Articles

Natural Biomolecule Ovomucin-Chitosan Oligosaccharide Self-Assembly Nanogel for Lutein Application Enhancement: Characterization, Environmental Stability and Bioavailability.

As an essential nutrient, lutein (LUT) has the ability to aid in the prevention of eye diseases, cardiovascular diseases, and cancer. However, the application of LUT is largely restricted by its poor solubility and susceptibility to oxidative degradation. Thus, in this study, LUT-loaded nanogel (OVM-COS-LUT) was prepared by a self-assembly of ovomucin (OVM) and chitosan oligosaccharide (COS) to enhance the effective protection and bioavailability of LUT. The nanogel had excellent dispersion (PDI = 0.25) and an 89.96% LUT encapsulation rate. XRD crystal structure analysis confirmed that the encapsulated LUT maintained an amorphous morphology. In addition, the nanogel showed satisfactory stability with pH levels ranging from 2 to 9 and high ionic strengths (>100 mM). Even under long-term storage, the nanogel maintained an optimistic stabilization and protection capacity; its effective retention rates could reach 96.54%. In vitro, digestion simulation showed that the bioaccessibility and sustained release of OVM-COS-LUT nanogel was superior to that of free LUT. The nanogel provided significant antioxidant activity, and no significant harmful effects were detected in cytotoxicity analyses at higher concentrations. In summary, OVM-COS-LUT can be utilized as a potential safe oral and functional carrier for encapsulating LUT.

Research Progress on Construction of Lutein-Loaded Nano Delivery System and Their Improvements on the Bioactivity

Lutein belongs to the diverse group of pigments known as oxygenated carotenoids, also known as phytochrome and macular pigment, demonstrating excellent biological activity. However, its application is limited due to the difficulty of dissolution, poor stability, and low bioavailability. To solve these problems, delivery systems are considered to be one of the most promising choices. These delivery systems can improve the physical, chemical, and biological properties of lutein to a certain extent. Moreover, the system can also be adapted to the needs of production in our daily life. In this paper, the construction of lutein-loaded nano delivery systems and their influences on the bioactivity of lutein were reviewed based on previous researchers. The main materials were classified, and assistant substances, basic parameters, and properties were collected. The mechanisms were analyzed in terms of enhancing cellular uptake, improving bioavailability, and achieving targeted delivery. These results show that different materials have their own characteristics. This review aims to provide references for the production and application of lutein in the food industry.

Biopolymer Stabilized Emulsions Improved Storage Stability and In Vitro Bioaccessibility of Lutein

ObjectivesLutein plays a critical role in the visual and cognitive development of infants. However, the application of lutein as a potential nutraceutical is limited by its low stability and poor water solubility. While various encapsulation systems have been developed for lutein to enhance its stability and bioavailability, few utilized bio-based polymers that are safe to use in infant foods. The aim of the study was to develop a novel emulsion system for lutein using food-grade colloids, octenylsuccinylated (OS) starch and gum Arabic (GA), as emulsifiers, which could improve the stability and bioaccessibility of lutein. MethodsLutein oil-in-water emulsions were prepared using two types of OS starch, capsule TA® (CTA) and HI-CAP®100 (HC), and one type of GA, TICAmulsion® 3020 (TM). Lutein was dissolved in olive oil and mixed with the aqueous biopolymer dispersions at 70% oil volume fraction using a homogenizer. The stabilities of the emulsion were assessed by measuring droplet size and distribution, changes of droplet size, and lutein retention at 25 and 45°C after a week of storage. The in vitro bioaccessibility of lutein was measured using a simulated in vitro gastrointestinal model. Free lutein was used as control. ResultsThe mean droplet size of lutein emulsions stabilized by CTA, HC, and TM were 1.19 ± 0.75, 1.45 ± 0.80, and 1.18 ± 0.8 μm, respectively. After a week of storage at 25°C, the particle size stabilized by OS starches did not change significantly, while GA-stabilized emulsion showed 1.58-fold larger droplet size than fresh sample (P < 0.05). Lutein retention in the control and emulsions stabilized by CTA, HC, and TM were 79%, 88%, 89%, and 86% at day 7, respectively. After a week of storage at 45°C, the emulsions stabilized by CTA, HC, and TM showed 1.34-, 2.38-, and 1.55- fold larger particle size compared to fresh samples (P < 0.05). The retention of lutein in free lutein and emulsions were 78%, 86%, 46%, and 63%, respectively. The in vitro bioaccessibility of lutein emulsions were 1.95-, 1.46-, and 1.27- fold higher than that of free lutein (P < 0.05). ConclusionsLutein emulsion stabilized by OS starch CTA had the best overall stability in droplet aggregation, color retention, and in vitro release. The oil-in-water emulsion stabilized by biopolymers could be promising carriers for lutein to expand their application in infant foods. Funding SourcesLouis/Evelyn Knol Fund.

Advances in Research on Natural Distribution, Biosynthesis, Detection, Bioactivity, and Application of Lutein

Advances in Research on Natural Distribution, Biosynthesis, Detection, Bioactivity, and Application of Lutein

Surface modified porous silicon with chitosan coating as a pH-responsive controlled delivery system for lutein.

Surface modified pH-responsive porous silicon (PSi) carriers were developed for efficient delivery of lutein. PSi particles were prepared by the electrochemical etching method and modified with two chemical groups: hydroxyl and octadecyl silane, respectively. Chitosan (CS) was used for coating of PSi to ensure pH-responsive release. The loading conditions, release properties, cytotoxicity and toxicity were investigated. The highest loading percentage of lutein could be obtained with oxidized PSi and the structure of the microparticles was characterized by Fourier transform-infrared spectroscopy. The surface area and pore size of the microparticles were obtained from the N2 adsorption-desorption isotherm. The CS-PSi-Lut microparticles showed the minimum surface area of 220.30 m2 g-1 and a relatively larger average pore width of 179.00 Å. In vitro release experiments showed a pH-responsive and controlled release of lutein, with the fastest release rate and highest cumulative release rate of 97% under acidic conditions (pH 5.0) within 7 h. PSi, chitosan and lutein showed synergistic toxic effects, and the CS-PSi-Lut microparticles could effectively inhibit the proliferation of HT-29 cells in a dose-dependent manner, with an inhibition rate of 77% when the lutein concentration reached 40 μg mL-1. The in vivo toxicological evaluation of CS-PSi-Lut microparticles indicated good biocompatibility in the range of experimental doses. The chitosan-coated oxidized PSi capable of delivering bioactive compounds in a targeted and controlled manner provides a novel platform for the development and application of lutein.

Novel formulation of liposomal lutein using nanofiber weaving (NFW) technology: Antioxidant property and in vitro release studies

Lutein is a xanthophyll carotenoid found in dark green leafy vegetables, fruits and flowers and displays potent biological properties many of which are believed to be related to its antioxidant properties. The application of lutein as a nutraceutical is limited by its low oral bioavailability, likely due to low water-solubility and poor chemical-stability. In this study, liposomal lutein (LL) was formulated in powder form via nanofiber weaving (NFW) technology, commercially known as Zeal Technology, to improve the oral bioavailability of lutein through enhanced chemical stability. LL has a particle size range of 70–200 nm with smooth surface, spherical shaped and an encapsulation efficiency of 85.96±2.41%, loading capacity 7.96±1.18%, and zeta potential -17.8±0.74 mV. The appearance of the identical X-ray diffraction pattern of lutein in LL with lower intensities and the reduced endothermic peak of lutein in LL and the shift to lower temperature indicate the optimum encapsulation of lutein onto the liposomal matrix by NFW technology. Chemical stability of LL was compared with purified lutein. LL illustrated stability while purified lutein was not stable after a 35-day stability study. It was also demonstrated that the antioxidant potential was enhanced by the complex with phospholipids via NFW technology. The release rate of LL was greater than that of purified lutein indicating that LL had a good sustainable release profile. These results reveal that LL could be a promising delivery system for lutein. Preparation of lutein by NFW technology may enable development of nutraceuticals with improved functional properties.

Stability, Cytotoxicity, and Retinal Pigment Epithelial Cell Binding of Hyaluronic Acid-Coated PLGA Nanoparticles Encapsulating Lutein.

The application of lutein was limited due to water insolubility and susceptible to heat and light degradation. In this study, hyaluronic acid (HA)-coated PLGA nanoparticles encapsulating lutein were fabricated by a solvent displacement method to improve the physicochemical properties and the stability of lutein. A biphasic release profile of lutein was observed, following zero-order release kinetics. The physical stability of lutein stored at 4°C, 30°C, and 40°C for 30days was enhanced when lutein was encapsulated in the nanoparticles. The degradation of lutein in PLGA NPs coated with HA was fitted to a second-order kinetic model. The rate constant increased with increasing storage temperature. The activation energy of lutein-NPs was 63.26kJ/mol. The half-lives of lutein in PLGA-NPs were about 49, 4, and 2days at a storage temperature of 4°C, 30°C, and 40°C, respectively. The results suggested that lutein-NPs should be stored at 4°C to prevent physical and chemical degradation. The photodegradation of lutein in NPs followed a second-order kinetic model. The rate constant was 0.0155mg-1mlday-1. Cell viability study revealed that HA-coated PLGA nanoparticles encapsulating lutein did not show toxicity against retinal pigment epithelial cells (ARPE-19). The NPs bound ARPE-19 cells in a time- and a dose-dependent manner. The binding efficiency of lutein-NPs decreased at higher concentrations, suggesting that the NPs might reach binding saturation capacity. In conclusion, HA-coated PLGA nanoparticles could be used to deliver lutein and improved physicochemical property of lutein. Graphical abstract ᅟ.

Stability of lutein encapsulated whey protein nano-emulsion during storage.

Lutein is a hydrophobic carotenoid that has multiple health functions. However, the application of lutein is limited due to its poor solubility in water and instability under certain conditions during storage. Hereby we generated lutein loaded nano-emulsions using whey protein isolate (WPI) or polymerized whey protein isolate (PWP) with assistance of high intensity ultrasound and evaluate their stability during storage at different conditions. We measured the particle size, zeta-potential, physical stability and lutein content change. Results showed that the PWP based nano-emulsion system was not stable in the tested Oil/Water/Ethanol system indicated by the appearance of stratification within only one week. The WPI based nano-emulsion system showed stable physiochemical stability during the storage at 4°C. The lutein content of the system was reduced by only 4% after four weeks storage at 4°C. In conclusion, our whey protein based nano-emulsion system provides a promising strategy for encapsulation of lutein or other hydrophobic bioactive molecules to expand their applications.

Improved oral bioavailability for lutein by nanocrystal technology: formulation development, in vitro and in vivo evaluation

Lutein is a kind of natural carotenoids possessing many pharmacological effects. The application of lutein was limited mainly due to its low oral bioavailability caused by poor aqueous solubility. Nanocrystal formulation of lutein was developed to improve the oral bioavailability in this study. The nanosuspension was prepared by the anti-solvent precipitation-ultrasonication method and optimized by Box–Behnken design, followed by freeze-drying to obtain lutein nanocrystals. The nanocrystals were characterized on their physical properties, in vitro dissolution and in vivo absorption performance. Lutein nanocrystals showed as tiny spheres with an average particle size of 110.7 nm. The result of diffractograms indicated that the percent crystallinity of lutein was 89.4% in coarse powder and then declined in nanocrystal formulation. The saturated solubility of lutein in water increased from 7.3 μg/ml for coarse powder up to 215.7 μg/ml for lutein nanocrystals. The dissolution rate of lutein nanocrystals was significantly higher than that of coarse powder or the physical mixture. The Cmax and AUC0–24 h of lutein nanocrystals after oral administration in rats was 3.24 and 2.28 times higher than those of lutein suspension, respectively. These results indicated that the nanocrystal formulation could significantly enhance the dissolution and absorption of lutein and might be a promising approach for improving its oral bioavailability.

Application of Lutein and Zeaxanthin in nonproliferative diabetic retinopathy.

To compare serum Lutein and Zeaxanthin (L/Z) concentrations between patients with nonproliferative diabetic retinopathy (NDR) and normal subjects, and to explore the effect of L/Z supplementation on serum L/Z level and visual function in NDR patients SUBJECTS WERE DIVIDED INTO THREE GROUPS: 30 NDR patients supplied with Lutein 6mg/d and Zeaxanthin 0.5mg/d for three months (DR Group), 30 NDR patients without L/Z supplementation (DR Control Group) and 30 normal subjects (Control Group). Serum L/Z concentrations were measured by liquid high-resolution chromatography (HPLC). Visual acuity was recorded at baseline, 1 month, 2 months and 3 months post initial supplementation. Serum L/Z concentration were measured at baseline, 1 month and 2 months post initial supplementation. Contrast sensitivity (CS) and fovea thickness were recorded at baseline and 3 months post initial supplementation. Mean serum lutein concentrations in DR group were 0.0686±0.0296µg/mL and zeaxanthin concentration was 0.0137±0.0059µg/mL. The L/Z level of DR group was significantly lower compared to the control group (lutein: 0.2302±0.1308µg/mL, zeaxanthin: 0.0456±0.0266µg/m, P=0.000). The concentration of lutein and zeaxanthin in the DR control group at base line was 0.0714±0.0357µg/mL and 0.0119±0.0072µg/mL, respectively. There was no significant change of L/Z concentration in the DR control group during the study. Serum L/Z concentrations of DR group increased significantly after supplementation (F=109.124, P=0.000; F=219.207, P=0.000). Visual acuity improved significantly after medication. Compared with pre-medication, the average CS values of 1.5cpd, 3cpd and 6cpd after three months increased significantly (P=0.030,0.013,0.008) and the foveal thickness decreased. (P=0.05) Serum L/Z concentrations in DR patients are significantly lower than those in normal subjects, and L/Z intake can improve the visual acuity, CS and macular edema in DR patients, suggesting that L/Z supplementation might be targeted as potential potential therapeutic agents in treating NDR.